Toxicology – Benzocaine-Induced Methemoglobinemia

Source

Benzocaine is a topical local anesthetic found in some throat sprays, lozenges, oral pain products, and preparations used to numb the mouth or throat before procedures such as endoscopy.

Typical Presentation

Shortly after receiving topical benzocaine, a patient may suddenly develop shortness of breath and bluish discoloration of the skin or lips despite receiving oxygen. This should raise concern for methemoglobinemia.

Clinical Features

The main toxic effect is methemoglobinemia. Depending on severity, patients may develop:

• Cyanosis
• Shortness of breath
• Headache or dizziness
• Fatigue or weakness
• Tachycardia
• Confusion or other neurological symptoms in severe cases

Mechanism of Action

Benzocaine normally produces local anesthesia by blocking sodium channels. However, its metabolites can oxidize the iron in hemoglobin from Fe²⁺ (ferrous) to Fe³⁺ (ferric), forming methemoglobin. Methemoglobin cannot effectively carry oxygen, resulting in impaired tissue oxygen delivery.

Management

• Immediately discontinue benzocaine exposure.
• Provide supportive care and supplemental oxygen.
• Significant or symptomatic methemoglobinemia is treated with IV methylene blue under appropriate medical supervision.
• Patients who cannot safely receive methylene blue may require alternative specialist-directed treatment.

Key Points

• Benzocaine is a classic medication-associated cause of methemoglobinemia.
• Think of methemoglobinemia when cyanosis develops unexpectedly after topical anesthetic use.
• Oxygen saturation may remain abnormally low despite supplemental oxygen.
• Benzocaine is also present in several over-the-counter oral numbing products.